This Web Site is committed to the memory of Janis Morrow.
Effects of Alcohol HCV Treatment and Your Liver
Effects of Alcohol
Jan 2009 http://www.hcvadvocate.org/
It is well known that heavy alcohol consumption can lead to severe liver disease including cirrhosis and hepatocellular carcinoma, but the effects of alcohol on HCV and its treatment are less well studied. As described in the December 15, 2008 Journal of Infectious Diseases, E. McCartney and colleagues performed a laboratory study using cultured Huh-7 cells to examine the effects of alcohol metabolism on HCV replication and the antiviral activity of interferon. They found that exposing the cells to ethanol significantly increased HCV replication, which was dependent on oxidative stress; when the researchers added NAC to the cell cultures, ethanol no longer increased HCV replication. Furthermore, the anti-HCV activity of interferon was also reduced in the presence of ethanol. "These in vitro results mimic what is often noted clinically," the researchers concluded, supporting the recommendation that people with chronic hepatitis C should avoid alcohol or consume only small amounts.
Effects of Alcohol on HCV Replication and Treatment Response
Alcohol Use as a Risk Factor for Poor Adherence and Treatment Failure
ALCOHOL AND ITS EFFECTS ON HEPATITIS C
Effects of Alcohol on HCV Replication and Treatment
Response
By Liz Highleyman
It is well
known that heavy alcohol consumption can lead to advanced liver disease,
including
cirrhosis and
hepatocellular carcinoma, but the effects of alcohol on
hepatitis C virus (HCV)
infection and its
treatment
are not fully understood.
As reported in the December 15, 2008 Journal of Infectious Diseases, Erin
McCartney from the University of Adelaide in Australia and colleagues conducted
a laboratory study to determine the effect of alcohol metabolism on HCV
replication and the antiviral activity of interferon.
The researchers used Huh-7 cells that allow for in vitro HCV replication and
metabolize ethanol via the introduced expression of cytochrome P450 2E1
(Cyp2e1). Cell cultures were exposed to ethanol and "treated" with interferon
alfa.
Results
Exposing the cells to ethanol (0-100 mmol/L) significantly increased HCV replication.
This effect was dependent on Cyp2e1 expression and alcohol-metabolized oxidative stress.
This was demonstrated by the fact that the antioxidant N-acetylcysteine blocked the effect.
The anti-HCV action of interferon alfa was reduced in the presence of ethanol, most likely via attenuation of Stat1 tyrosine-701 phosphorylation.
"These in vitro results
mimic what is often noted clinically," the researchers concluded. "[F]urther
dissection of this model system will aid in our understanding of interactions
between HCV and alcohol metabolism."
These findings serve to underline the recommendation that people with chronic
hepatitis C or other types of liver disease should avoid alcohol entirely or
consume it only in small amounts.
Infectious Diseases Laboratories, Institute of Medical and Veterinary
Science, and School of Molecular and Biomedical Sciences, University of
Adelaide, Adelaide, Australia; Digestive Diseases Laboratory, Northern Clinical
School, University of Sydney, Sydney, Australia; Department of Neuroscience and
Cell Biology, University of Texas Medical Branch, Galveston, TX.
1/13/09
Reference
EM McCartney, L Semendric, KJ Helbig, and others. Alcohol Metabolism Increases
the Replication of Hepatitis C Virus and Attenuates the Antiviral Action of
Interferon. Journal of Infectious Diseases 198(12): 1766-1775. December 15,
2008. (Abstract).
http://www.hivandhepatitis.com/hep_c/news/2009/011309_a.html
Alcohol Use as a Risk Factor for Poor
Adherence and Treatment Failure
![]() |
As reported in the
December 1, 2006 Journal of Acquired Immune Deficiency Syndromes,
researchers examined the independent effect of alcohol and the combined effects
of alcohol and illicit drug use on antiretroviral therapy utilization,
adherence, and virological suppression in an urban cohort of HIV positive
individuals.
In this observational clinical cohort, alcohol use, active drug use, and
adherence were prospectively assessed at 6-month intervals. The investigators
classified "hazardous alcohol use" as more than 7 drinks per week or more than 3
drinks on one occasion for women, and more than 14 drinks per week or more than
4 drinks on one occasion for men. Active drug use was defined as any use within
the previous 6 months. Outcomes included utilization of antiretroviral therapy,
2-week adherence, and virological suppression. Analyses were adjusted for age,
sex, race, years on antiretroviral therapy, and clinic enrollment time.
Results
• Between 1998 and 2003, 1711 individuals participated in 5028 interviews.
• 1433 of these patients (accounting for 3761 interviews) were on antiretroviral therapy.
•The prevalence of any alcohol use at the first interview was 45%, with 10% classified as hazardous drinkers.
•One-third of the sample used illicit drugs.
• In multivariate analyses adjusting for age, sex, race, active drug use, years on antiretroviral therapy, and clinic enrollment time, hazardous alcohol use, compared with no alcohol use, was independently associated with:
- decreased antiretroviral therapy utilization (AOR 0.65; 95% CI 0.51 to 0.82);
- poorer 2-week adherence (AOR 0.46; 95% CI 0.34 to 0.63);
- reduced virological suppression (AOR 0.76; 95% CI 0.57 to 0.99)
• Concurrent injection drug use exacerbated these negative effects on antiretroviral therapy use, adherence, and virological suppression.
Conclusion
"Hazardous alcohol use alone and combined with injection drug use was associated
with decreased antiretroviral therapy uptake, adherence, and viral suppression,"
the authors concluded. "Interventions targeting alcohol use may improve HIV
outcomes in individuals with hazardous alcohol use."
Department of Medicine, Johns Hopkins University School of Medicine,
Baltimore, MD.
12/12/06
Reference
G Chander, B Lau, R D Moore. Hazardous Alcohol Use: A Risk Factor for
Non-Adherence and Lack of Suppression in HIV Infection. Journal of Acquired
Immune Deficiency Syndromes 43(4): 411-417, December 1, 2006.
http://www.hivandhepatitis.com/recent/2007/011207_e.html
